A gene defect as a potential gateway for targeted prostate cancer therapy

September 5, 2016, European Molecular Biology Organization

The loss of CHD1, one of the most frequently mutated genes in prostate tumors, sensitizes human prostate cancer cells to different drugs, including PARP inhibitors. This suggests CHD1 as a potential biomarker for targeted prostate cancer therapy. These are the results of a study published today in EMBO Reports.

A team of researchers in Germany and Denmark led by Steven Johnsen, Professor at the University Medical Center Göttingen, Germany, used human prostate cancer cell lines and depleted them of the DNA-binding protein CHD1. The CHD1 gene is mutated in 15-27% of all , and such mutations correlate with chromosomal instability and poor prognosis for prostate cancer patients. The researchers could demonstrate that CHD1-depleted cells have defects in homologous recombination (HR), an important mechanism for repairing breaks in the DNA molecule. The data indicate that CHD1's normal function is the loosening of DNA around break sites in order to facilitate the access of HR repair proteins. Importantly, like with other mutations in the HR repair pathway, CHD1-depleted proved to be hypersensitive to chemotherapeutic drugs causing DNA breaks, such as Mitomycin C, Irinotecan and PARP inhibitors.

"I am very excited about the translational potential of the study, and we are getting into contact with pharmaceutical companies to try to translate these findings into clinical development," Johnsen says. In particular, it has been shown that cells with other HR repair pathway defects, such as BRCA mutations frequently found in breast and ovarian cancer, are sensitive to inhibition of the enzyme PARP, and the PARP inhibitor Olaparib has been approved for treatment of BRCA-mutated ovarian cancers.

At this stage, PARP inhibitors are being tested in prostate cancer treatment, with a phase II clinical trial of Olaparib demonstrating increased radiologic progression-free survival in patients with metastatic prostate cancer displaying genomic aberrations indicative of HR repair defects. "A retrospective analysis of the CHD1 gene in these samples may reveal the potential utility of CHD1 as a biomarker for improved patient stratification and targeted therapy with PARP inhibitors," notes Johnsen.

Explore further: BRCA-targeting drugs could treat prostate cancer, leading expert says

More information: EMBO Reports, Loss of CHD1 causes DNA repair defects and enhances prostate cancer therapeutic responsiveness, Vijayalakshmi Kari, Wael Mansour, Sanjay Raul, Simon Baumgart, Andreas Mund, Marian Grade, Hüseyin Sirma, Ronald Simon, Hans Will, Matthias Dobbelstein, Ekkehard Dikomey, Steven Johnsen, DOI: 10.15252/embr.201642352 , http://embor.embopress.org/content/early/2016/09/05/embr.201642352

Related Stories

BRCA-targeting drugs could treat prostate cancer, leading expert says

November 5, 2014
A pioneering cancer drug set to become the first to be approved specifically for inherited cancers could also be used much more widely to treat prostate cancer, a world-leading expert said today.

New findings may enhance PARP inhibitors therapy in breast cancer

January 18, 2016
Findings from a new study reveal that PARP inhibitors, an emerging class of drugs being studied in cancer clinical trials, may be enhanced by combining them with inhibitors targeting an oncogene known as c-MET which is overexpressed ...

Synthetic plant hormones shut down DNA repair in cancer cells

February 16, 2016
Two drugs that mimic a common plant hormone effectively cause DNA damage and turn off a major DNA repair mechanism, suggesting their potential use as an anti-cancer therapy, say investigators at Georgetown University Medical ...

World-first cancer drugs could work in larger group of patients

March 19, 2015
A pioneering class of drugs that target cancers with mutations in the BRCA breast cancer genes could also work against tumours with another type of genetic fault, a new study suggests.

Testing for inherited mutations could benefit men with advanced prostate cancer

July 6, 2016
Inherited mutations in genes that function to repair DNA may contribute to metastatic prostate cancer more than previously recognized, according to a study out today in the New England Journal of Medicine. Though infrequent ...

New class of cancer drugs could work in colon cancers with genetic mutation, study finds

April 25, 2011
A class of drugs that shows promise in breast and ovarian cancers with BRCA gene mutations could potentially benefit colorectal cancer patients with a different genetic mutation, a new study from the University of Michigan ...

Recommended for you

Scientists discover how breast cancer hibernates: study

May 22, 2018
Scientists have identified the mechanism that allows breast cancer cells to lie dormant in other parts of the body only to reemerge years later with lethal force, according to a study published Tuesday.

Researcher: Big data, networks identify cell signaling pathways in lung cancer

May 22, 2018
A team of scientists led by University of Montana cell biologist Mark Grimes has identified networks inside lung cancer cells that will help understand this cancer and fight it with drug treatments.

Resetting the epigenetic balance for cancer therapy

May 22, 2018
Though mutations in a gene called MLL3 are common across many types of cancers, their relationship to the development of the disease has been unclear. Now, a Northwestern Medicine study has identified an epigenetic imbalance ...

Downward-facing mouse: Stretching reduces tumor growth in mouse model of breast cancer

May 22, 2018
Many cancer patients seek out gentle, movement-based stretching techniques such as yoga, tai chi and qigong, but does stretching have an effect on cancer? While many animal studies have attempted to quantify the effects of ...

Compound in citrus oil could reduce dry mouth in head, neck cancer patients

May 21, 2018
A compound found in citrus oils could help alleviate dry mouth caused by radiation therapy in head and neck cancer patients, according to a new study by researchers at the Stanford University School of Medicine.

Ice cream funds research showing new strategy against thyroid cancer

May 21, 2018
Anaplastic thyroid cancer is almost uniformly fatal, with an average lifespan of about 5 months after diagnosis. And standard treatment for the condition includes 7 weeks of radiation, often along with chemotherapy.

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.